Bicycle Therapeutics plc (NASDAQ:BCYC) COO Alistair Milnes Sells 4,578 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) COO Alistair Milnes sold 4,578 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $64,504.02. Following the sale, the chief operating officer now owns 100,724 shares in the company, valued at approximately $1,419,201.16. The trade was a 4.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $14.88 on Tuesday. Bicycle Therapeutics plc has a 52 week low of $12.17 and a 52 week high of $28.67. The stock has a 50 day moving average price of $19.27 and a two-hundred day moving average price of $21.86. The firm has a market capitalization of $1.03 billion, a P/E ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same period in the prior year, the firm posted ($1.26) EPS. Bicycle Therapeutics’s quarterly revenue was down 50.0% compared to the same quarter last year. On average, equities analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BCYC shares. Stephens initiated coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. JMP Securities decreased their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Bicycle Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BCYC. Assetmark Inc. bought a new stake in Bicycle Therapeutics in the 3rd quarter worth about $34,000. GAMMA Investing LLC grew its holdings in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after acquiring an additional 1,038 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after acquiring an additional 2,918 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after acquiring an additional 1,782 shares during the period. Finally, XTX Topco Ltd purchased a new position in Bicycle Therapeutics in the second quarter worth $206,000. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.